Zobrazeno 1 - 10
of 75
pro vyhledávání: '"AZUSA KOMORI"'
Autor:
Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective stu
Externí odkaz:
https://doaj.org/article/e7f02c7dbce94342bdbac0633ca1ffca
Autor:
Tomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, Taiga Otsuka, Masahiro Kawahira, Junichi Nakazawa, Takeshi Hori, Taro Shibuki, Shiho Arima, Akio Ido, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Kenji Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy a
Externí odkaz:
https://doaj.org/article/eebc9af936314345b048057f5416b5fd
Autor:
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in c
Externí odkaz:
https://doaj.org/article/f5f37084f80443099bd5a4c15daea257
Autor:
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflammatory marker, we investigated rel
Externí odkaz:
https://doaj.org/article/bc6dd35d26fe4df2aa0b662a99f00fd2
Autor:
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/10e1b3b0ad7e4fab943321b093b93e3e
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis
Externí odkaz:
https://doaj.org/article/eb35e2af95fa4d798ff5388601ac6ee0
Autor:
Shigenori Kadowaki, Yasushi Yatabe, Hitoshi Hirakawa, Azusa Komori, Chihiro Kondoh, Yasuhisa Hasegawa, Kei Muro
Publikováno v:
Case Reports in Oncology, Vol 6, Iss 3, Pp 450-455 (2013)
Introduction: Carcinoma ex pleomorphic adenoma (CXPA) of the salivary glands has often a salivary duct carcinoma (SDC) component, which resembles ductal carcinoma of the breast and frequently overexpresses human epidermal growth factor receptor-2 (HE
Externí odkaz:
https://doaj.org/article/5b645532f160420086f128ebbedf4bc3
Autor:
YASUSHI IDE, TAIGA OTSUKA, MOTOTSUGU SHIMOKAWA, FUTA KOGA, YUJIRO UEDA, JUNICHI NAKAZAWA, AZUSA KOMORI, SATOSHI OTSU, SHIHO ARIMA, MASARU FUKAHORI, AKITAKA MAKIYAMA, YUDAI SHINOHARA, SHOHEI UENO, HIROKI TAGUCHI, TAKUYA HONDA, TARO SHIBUKI, KENTA NIO, NORIO URESHINO, TOSHIHIKO MIZUTA, KENJI MITSUGI, TSUYOSHI SHIRAKAWA
Publikováno v:
Anticancer Research. 43:1817-1826
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22800627150461a7173ef79735b8dec4
https://doi.org/10.21873/anticanres.16335
https://doi.org/10.21873/anticanres.16335
Autor:
Azusa Komori, Satoshi Otsu, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Yoshinobu Okabe, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Tsuyoshi Shirakawa, Kenji Mitsugi
Publikováno v:
International Journal of Clinical Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e708dc50636a9ac6c197ff6c1874ee0f
https://doi.org/10.1007/s10147-023-02354-6
https://doi.org/10.1007/s10147-023-02354-6
Autor:
Futa Koga, Satoshi Otsu, Kenta Nio, Mototsugu Shimokawa, Akitaka Makiyama, Takuya Honda, Shiho Arima, Yujiro Ueda, Junichi Nakazawa, Masaru Fukahori, Taiga Otsuka, Norio Ureshino, Hiroki Taguchi, Azusa Komori, Yasushi Ide, Toshihiko Mizuta, Shinichi Hashimoto, Kenji Mitsugi, Tsuyoshi Shirakawa, Taro Shibuki, Akio Ido
Publikováno v:
Anticancer Research. 41:3573-3582
Background/aim The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection. Patients and methods Forty-four patients with rPC and 211 with de n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eab3665f8ca898a7656783e23f9dbf80
https://doi.org/10.21873/anticanres.15145
https://doi.org/10.21873/anticanres.15145